Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.62 |
| ▸ | CA2 | P00918 | 6/20 | 0.62 |
| ▸ | TGM2 | P21980 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999924 | 1.00 | CA1 (0.62) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL23647047 | 1.00 | CA1 (0.62) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL5751027 | 0.86 | CES1 (0.61) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL18505823 | 0.83 | TGM2 (0.61) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL5740900 | 0.79 | TGM2 (0.61) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL5739473 | 0.79 | CA1 (0.62) | CA1CA2LRRK2CA12CA9 | |
| SCHEMBL5740077 | 0.79 | TGM2 (0.61) | CA1CA2TGM2CES1LRRK2 | |
| SCHEMBL20436333 | 0.79 | CA1 (0.62) | CA1CA2LRRK2CA12CA9 | |
| SCHEMBL12805226 | 0.79 | CA1 (0.62) | CA1CA2LRRK2CA12CA9 | |
| SCHEMBL5739845 | 0.79 | CA1 (0.62) | CA1CA2LRRK2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945809-B2 | Isatin derivatives | KING SAUD UNIVERSITY (SA) | 2024-04-02 | — | — | US | claimed |
| US-20230357213-A1 | ISATIN DERIVATIVES | KING SAUD UNIVERSITY (SA) | 2023-11-09 | — | — | US | claimed |
| US-20210221794-A1 | ISATIN DERIVATIVES | KING SAUD UNIVERSITY (SA) | 2021-07-22 | — | — | US | claimed |
| US-12319674-B2 | Isatin derivatives | KING SAUD UNIVERSITY (SA) | 2025-06-03 | — | — | US | disclosed |
| US-20240239773-A1 | ISATIN DERIVATIVES | KING SAUD UNIVERSITY (SA) | 2024-07-18 | — | — | US | disclosed |
| US-11945809-B2 | Isatin derivatives | KING SAUD UNIVERSITY (SA) | 2024-04-02 | — | — | US | disclosed |
| US-20230357213-A1 | ISATIN DERIVATIVES | KING SAUD UNIVERSITY (SA) | 2023-11-09 | — | — | US | disclosed |
| US-20210221794-A1 | ISATIN DERIVATIVES | KING SAUD UNIVERSITY (SA) | 2021-07-22 | — | — | US | disclosed |
| EP-0570817-B1 | Process for the preparation of 5-chloroxindole | LONZA AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| US-5395963-A | Process for chloronitroacetic acid esters | LONZA LTD. (CH) | 1995-03-07 | — | — | US | disclosed |
| US-5284960-A | Process for the production of 5-chloroxindole | LONZA LTD. (CH) | 1994-02-08 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
| EP-0175551-A1 | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4569942-A | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0164860-A1 | N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0156603-A2 | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357213-A1 | ISATIN DERIVATIVES | HASPIN, BRCA1, VHL | CA1 4228/4885CA2 4626/4885TGM2 3844/4885 |
| US-12319674-B2 | Isatin derivatives | HASPIN, BRCA1, VHL | CA1 4228/4885CA2 4626/4885TGM2 3844/4885 |
| US-20240239773-A1 | ISATIN DERIVATIVES | HASPIN, BRCA1, VHL | CA1 4228/4885CA2 4626/4885TGM2 3844/4885 |
| US-20210221794-A1 | ISATIN DERIVATIVES | HASPIN, MCL1, BRCA1 | CA1 248/4885CA2 1060/4885TGM2 4478/4885 |
| US-11945809-B2 | Isatin derivatives | HASPIN, BRCA1, VHL | CA1 4228/4885CA2 4626/4885TGM2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.